Gotowa bibliografia na temat „Sustained release lithium”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Spis treści
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Sustained release lithium”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "Sustained release lithium"
Astruc, B., P. Petit i M. Abbar. "Overdose with sustained-release lithium preparations". European Psychiatry 14, nr 3 (czerwiec 1999): 172–74. http://dx.doi.org/10.1016/s0924-9338(99)80737-8.
Pełny tekst źródłaBosse, George M., i Thomas C. Arnold. "Overdose with sustained-release lithium preparations". Journal of Emergency Medicine 10, nr 6 (listopad 1992): 719–21. http://dx.doi.org/10.1016/0736-4679(92)90531-w.
Pełny tekst źródłaHeim, W., H. Oelschläger, J. Kreuter i B. Oerlinghausen. "Liberation of Lithium from Sustained Release Preparations". Pharmacopsychiatry 27, nr 01 (styczeń 1994): 27–31. http://dx.doi.org/10.1055/s-2007-1014270.
Pełny tekst źródłaHrdlička, M., i P. Ševčík. "Lethal lithium poisoning with sustained-release preparations". British Journal of Psychiatry 171, nr 6 (grudzień 1997): 586. http://dx.doi.org/10.1192/bjp.171.6.586a.
Pełny tekst źródłaKang, Hyeonmuk, Taehee Kim, GyuSeong Hwang, GeunHyeong Shin, Junho Lee i EunAe Cho. "Sustained Release of AgNO3 Additive in Carbonate Electrolytes for Stable Lithium Metal Anodes". ECS Meeting Abstracts MA2022-01, nr 4 (7.07.2022): 526. http://dx.doi.org/10.1149/ma2022-014526mtgabs.
Pełny tekst źródłaFriedberg, Richard C., Daniel A. Spyker i David A. Herold. "Massive overdoses with sustained-release lithium carbonate preparations: pharmacokinetic model based on two case studies". Clinical Chemistry 37, nr 7 (1.07.1991): 1205–9. http://dx.doi.org/10.1093/clinchem/37.7.1205.
Pełny tekst źródłaBorrás-Blasco, Joaquín, Ana Esther Sirvent, Andrés Navarro-Ruiz, Ana Murcia-López, Isabel Romero-Crespo i Ricardo Enriquez. "Unrecognized Delayed Toxic Lithium Peak Concentration in an Acute Poisoning with Sustained Release Lithium Product". Southern Medical Journal 100, nr 3 (marzec 2007): 321–23. http://dx.doi.org/10.1097/01.smj.0000257619.25995.c4.
Pełny tekst źródłaLlabrés, M., i J. B. Fariña. "Gastro-intestinal bioavailability assessment of commercialy prepared sustained-release lithium tablets using a deconvolution technique". Drug Development and Industrial Pharmacy 15, nr 11 (styczeń 1989): 1827–41. http://dx.doi.org/10.3109/03639048909052403.
Pełny tekst źródłaGregson, P. J., i I. Sinclair. "Deviant Crack Path Behaviour of Aluminium-Lithium Alloy AA8090 Plate". Proceedings of the Institution of Mechanical Engineers, Part G: Journal of Aerospace Engineering 210, nr 2 (kwiecień 1996): 117–21. http://dx.doi.org/10.1243/pime_proc_1996_210_352_02.
Pełny tekst źródłaGai, M. N., A. M. Thielemann i A. Arancibia. "Effect of three different diets on the bioavailability of a sustained release lithium carbonate matrix tablet". Int. Journal of Clinical Pharmacology and Therapeutics 38, nr 06 (1.06.2000): 320–26. http://dx.doi.org/10.5414/cpp38320.
Pełny tekst źródłaRozprawy doktorskie na temat "Sustained release lithium"
Couffignal, Camille. "Variabilité de la réponse pharmacologique, modélisation et influence des plans expérimentaux". Electronic Thesis or Diss., Université Paris Cité, 2021. http://www.theses.fr/2021UNIP5250.
Pełny tekst źródłaThe increasing number of patients with chronic diseases, most of whom are subject to long-term treatment, justifies the exploration and characterisation of phenotypic and genetic factors of pharmacological response. The identification and estimation of the pharmacokinetic-pharmacodynamic variability involved in the response to a treatment are essential steps in this exploration to achieve precision medicine. We studied the re-introduction of β-blockers after cardiac surgery in a prospective multicentre cohort of patients receiving chronic β-blocker therapy and who underwent cardiac surgery. With a landmark analysis, we have shown the efficacy of reintroducing β-blockers 72 hours after cardiac surgery on the occurrence of atrial fibrillation. We modelled, using a population approach, the serum, erythrocyte and urine concentration data of once-daily sustained-release lithium in bipolar patients undergoing treatment for at least two years. A clinical research protocol was then written, with an optimization of sampling times, based on the pharmacokinetic model obtained, to characterise inter- and intra-individual variability and to identify predictive factors of the prophylactic response to lithium. We evaluated, by simulation, the impact of the crossover versus parallel design, as well as the choice of statistical model during the analysis, in pharmacogenetic studies evaluating two treatments (candidate and reference) when a genetic polymorphism increases or not the efficacy of the candidate treatment compared to the reference. The results of this simulation study show that the choice of the model and the choice of the experimental design strongly affect not only the type I error and the power to detect a gene-treatment interaction, but also the correct allocation of the treatment. This work reinforces the need to use adequate statistical tools and experimental designs in the analysis of a clinical trial or pharmacoepidemiological study to characterize and quantify the variability of the pharmacological response